# CJC-1295: Research Overview > CJC-1295: Research Overview — Definitive Peptides — A cited research overview of CJC-1295, a long-acting growth-hormone-releasing hormone analog. Mechanism, human pharmacology trial results, DAC vs no-DAC distinction, and safety cautions. **04 / RESEARCH PEPTIDE FUNDAMENTALS** A long-acting GHRH analog that keeps growth hormone elevated for days — studied in a handful of small human pharmacology trials, never approved, and flagged by FDA reviewers for immunogenicity concerns. ## The short version CJC-1295 is a lab-modified version of growth-hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone. Ordinary GHRH breaks down in minutes; CJC-1295 is engineered to last for days, so a single dose keeps growth hormone and its downstream signal, IGF-1, elevated far longer than the body's own rhythm normally allows. It comes in two forms that are often confused: the long-acting "DAC" version that binds to a blood protein and lasts several days, and the short-acting "no-DAC" version (Modified GRF 1-29) that lasts only minutes to hours. Neither form is approved for human use anywhere. Published human data are limited to a small number of early pharmacology studies in healthy adults, and a 2024 FDA advisory committee flagged immunogenicity concerns when reviewing whether it should be compoundable. ## What it is CJC-1295 is a synthetic GHRH analog built on the first 29 residues of human growth-hormone-releasing factor, hGRF(1-29), carrying four amino-acid substitutions that stabilize its structure and block the enzymatic breakdown, deamidation and oxidation that limit natural GHRH. In the DAC ("Drug Affinity Complex") form, a chemical linker lets the peptide form a covalent bond with a free site on circulating albumin, extending its half-life toward that of albumin itself — days rather than minutes. The no-DAC form keeps the same four substitutions but skips the albumin-binding chemistry, making it short-acting. ## How it works CJC-1295 binds the GHRH receptor on growth-hormone-producing cells in the anterior pituitary, activating a signaling cascade that stimulates synthesis and pulsatile release of growth hormone, which then raises IGF-1 output from the liver. Because the DAC form's protease resistance and albumin binding together produce a multi-day half-life, a single dose elevates GH and IGF-1 for days at a time — while research has found that the body's normal pulsatile pattern of GH release is still preserved rather than replaced by a flat, continuous signal [22]. ## What the research shows *Mechanism context.* A 2024/2025 review in Nature Reviews Endocrinology synthesizes the pharmacology of GHRH and its synthetic analogs — the class that includes CJC-1295 alongside sermorelin and tesamorelin — covering receptor signaling and the design rationale behind long-acting analogs [18]. *Confirmed in a seized black-market product.* High-resolution mass spectrometry identified CJC-1295 as the active ingredient in an unknown "GHRH" preparation seized in an anti-doping context — direct confirmation the compound circulates outside any regulated supply chain [19]. *Human pharmacology.* In 11 healthy young men, CJC-1295 shifted the serum protein profile in ways that correlated with IGF-1 levels, identifying candidate biomarkers of GH-axis activation [20]. In a separate study of healthy adults aged 21-61, single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent, 2- to 10-fold increases in mean plasma GH lasting 6 days or more, with IGF-1 elevated 1.5- to 3-fold for 9-11 days; after repeated dosing, IGF-1 stayed above baseline for up to 28 days, and the estimated half-life of CJC-1295 itself was 5.8 to 8.1 days [21]. *Preserved pulsatility.* In healthy men aged 20-40, a single dose (60 or 90 micrograms per kilogram) raised basal GH roughly 7.5-fold and mean GH by about 46%, with IGF-1 up about 45% one week later — while the frequency and size of the body's normal pulsatile GH bursts were unchanged, indicating natural GH rhythm persists even under sustained GHRH-analog stimulation [22]. ## Reported effects, cautions & safety *Reported in research-use communities — anecdotal, not clinical evidence, and never a dose:* Deeper, more restful sleep is the single most commonly reported effect, often noticed within the first week, which fits the known biology since growth hormone release peaks during deep sleep. Many users also describe faster recovery from training soreness and gradual fat loss, especially around the midsection, over several weeks. Some report a leaner look, more daytime energy, or sharper focus, generally attributed to better sleep and recovery rather than a direct effect. On the downside, water retention and puffiness are the most commonly reported complaint, described as more pronounced with the long-acting DAC form; tingling or numbness in the hands, often compared to mild carpal tunnel, and injection-site reactions are also frequently mentioned. A smaller number of users report fatigue, headache, or, when combined with other GH-secretagogue peptides, increased appetite. *Cited safety cautions:* - **CJC-1295 is not approved for human use anywhere.** Published human evidence is limited to a small number of early pharmacology studies; there are no large or long-term trials establishing safety or efficacy in healthy adults [21]. - **Immunogenicity was flagged by FDA reviewers.** In 2024 FDA briefing materials for the Pharmacy Compounding Advisory Committee, immunogenicity and other safety concerns were cited as part of the basis for not recommending CJC-1295 for the pharmacy-compounding bulk-substances list [18]. - The wider literature also documents mechanism-based cautions worth knowing: because growth hormone raises IGF-1, and higher circulating IGF-1 has been linked in population studies to a modestly increased risk of certain cancers, sustained IGF-1 elevation is a theoretical concern for anyone with a personal or family cancer history. Growth hormone also causes the kidneys to retain sodium and water, which is the likely driver of the fluid retention and nerve-compression symptoms reported above, and it is glucose-sparing, which can reduce insulin sensitivity with prolonged use. CJC-1295 is prohibited at all times in competitive sport under WADA's peptide-hormone category, and the DAC and no-DAC forms are routinely and consequentially confused in marketing and forum discussion, since the two behave very differently in the body. ## Where it fits in research peptide fundamentals CJC-1295 sits alongside [BPC-157](/bpc-157) and [MOTS-c](/mots-c) as one of three compounds on this desk with no approved human indication anywhere, but it is distinguished by having a small, genuine body of controlled human pharmacology data — unlike BPC-157's near-total reliance on rodent work. It is also the clearest example on this desk of how a single compound name can hide two pharmacokinetically distinct products (DAC and no-DAC), a distinction the [comparison page](/compare) treats explicitly. --- Definitive Peptides is an independent research desk that traces every claim on this site to a cited source — not a clinic, not a supplier, and never a substitute for a licensed clinician's judgment.